In this study, we established an experimental therapeutic platform of cellular immunotherapy targeting for PCSCs based on the cytokine-induced killer T cells specifically activated by dendritic cells (DC-CIK) which had been preloaded or sensitized with immunogenic peptides derived from two PCSC-associated membrane antigens, CD44 and epithelial cell adhesion molecule (EpCAM or CD326), and both have been utilized as potential therapeutic targets via different approaches for prostate cancer. This evidence concerns the gene CD44 and Familial prostate cancer.